^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:letrozole (Aromatase inhibitor) +
    amcenestrant (SAR439859) (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res
    Title:

    AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer

    Published date:
    11/10/2023
    Excerpt:
    Both amcenestrant and letrozole demonstrated antiproliferative activity in postmenopausal women with previously untreated, operable ER+/HER2− breast cancer and had good overall tolerability.
    DOI:
    10.1186/s13058-023-01740-2
    Trial ID:
    AMEERA-4